RiverVest Funds I, II & III RiverVest Fund IV Archer Seed Fund

14 Dec

Posted at 15:37h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAAvalyn is a biopharma company developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The lead asset is inhaled pirfenidone (Aerodone™) for the treatment of...

14 Dec

Posted at 15:34h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} St. Louis, MOWith RiverVest as a founder, Arch Oncology is focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with solid-tumor and certain blood cancers. Arch Oncology’s next-generation...

14 Dec

Posted at 15:28h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Boston, MAXilio is an oncology company developing highly-potent, tumor-selective immunotherapies to improve patient outcomes. With an anti-CTLA4 antibody as validation, the company’s technology is also being applied to cytokines, which currently have limited or...

14 Dec

Posted at 15:06h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Seattle, WAOncoResponse is leveraging a proprietary human antibody platform to discover novel targets and identify fully-human monoclonal antibodies as therapeutics for the treatment of cancer, potentially extending cures to patients who otherwise would not...

14 Dec

Posted at 15:04h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} St. Louis, MOOxaluRx is a preclinical company developing a small molecule, oral therapy to treat primary hyperoxaluria, a rare orphan metabolic disease. This rare form of hyperoxaluria is due exclusively to a genetic defect...

14 Dec

Posted at 15:03h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAIPO April 2021 (NASDAQ: RPHM)Reneo, a RiverVest-founded company, is a clinical-stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with...

14 Dec

Posted at 15:01h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Philadelphia, PAScout is focused on delivering a new generation of gene therapies for pets to significantly improve the standard-of-care for multiple conditions. The technology approach is to express an appropriate level of a therapeutic...

14 Dec

Posted at 14:58h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CAIPO October 2020 (NASDAQ: SPRB)Spruce is developing novel therapies for rare endocrine diseases. The company’s lead product candidate for the treatment of congenital adrenal hyperplasia (CAH) is intended to correct hormone imbalances,...

14 Dec

Posted at 14:20h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} St. Louis, MOWugen is developing a novel chimeric antigen receptor (CAR-T) therapy platform for T-cell malignancies. Wugen’s state-of-the-art gene editing and CAR-T cell technology enable “off-the-shelf” therapies that would avoid rejection by the recipient....

14 Dec

Posted at 14:18h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CAIPO July 2018 (NASDAQ: ALLK)Allakos is a clinical-stage biotechnology company developing therapeutic antibodies targeting a broad range of allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, AK002, targets Siglec-8, an inhibitory receptor...

13 Dec

Posted at 21:13h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CAIPO July 2019 (NASDAQ: MIRM)Mirum was formed, with support from RiverVest, to develop the compound previously developed by Lumena (see Lumena discussion above).  After Takeda’s acquisition of Shire, the compound, now called...

13 Dec

Posted at 20:50h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Portland, ORSparrow Pharmaceuticals was founded to spare patients the ravages of corticosteroids. Leveraging underappreciated scientific insights into steroid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and...

13 Dec

Posted at 20:48h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Carlos, CAGlycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes,...

13 Dec

Posted at 20:45h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Waltham, MASeQure Dx, Inc. is applying state-of-the-art genomics technologies for gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. Their core technologies, GUIDE-seq and ONE-seq, enable identification of all potential off-target...

13 Dec

Posted at 20:41h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CABluejay Therapeutics develops innovative cures for infectious diseases. The first target indication is chronic HBV infection (CHBV). Bluejay has in-licensed three promising assets from Novartis that use different mechanisms to contribute to...